Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Discussion: Verifying Predictive Models for Determining Final Implant Volume in 2-Stage Implant-Based Breast Reconstruction.

Plastic and reconstructive surgery·2026

Same author

Exploring the Role of Neutrophils in Pathogenesis of Lymphangioleiomyomatosis.

Journal of innate immunity·2026

Same author

Epidemiology and Clinical Characteristics of Pulmonary Alveolar Proteinosis in Guangdong, China.

Chest·2026

Same author

Radiation-triggered acute exacerbation of progressive fibrotic interstitial lung diseases: 'Are we advancing the frontier or crossing a dangerous line?'

Therapeutic advances in respiratory disease·2026

Same author

Current insight into molecular mechanisms of Lymphangioleiomyomatosis.

American journal of respiratory cell and molecular biology·2026

Same author

Idiopathic pulmonary fibrosis risk loci in East Asian populations mirror those of European populations.

American journal of respiratory and critical care medicine·2026

Search research articles

Related Experiment Video

Updated: Jan 15, 2026

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

Recombinant GM-CSF drug evaluation review.

Jack McCarthy¹, Niamh Boyle^1,2, Cormac McCarthy^1,2

¹Department of Respiratory Medicine, St. Vincent's University Hospital, Dublin, Ireland.

|October 14, 2025

Summary

Autoimmune Pulmonary Alveolar Proteinosis (aPAP) is a rare lung disease. Inhaled recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) improved patient health and lung function, offering a safe treatment alternative.

Keywords:

GM-CSF Interstitial lung disease Macrophage PAP Recombinant GM-CSF autoimmune pulmonary alveolar proteinosis granulocyte macrophage colony stimulating factor

More Related Videos

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Published on: November 11, 2021

Culture of myeloid dendritic cells from bone marrow precursors

Culture of myeloid dendritic cells from bone marrow precursors

Published on: July 25, 2008

Related Experiment Videos

Last Updated: Jan 15, 2026

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

Published on: November 11, 2021

Culture of myeloid dendritic cells from bone marrow precursors

Culture of myeloid dendritic cells from bone marrow precursors

Published on: July 25, 2008

Area of Science:

Pulmonary Medicine
Immunology
Rare Diseases

Background:

Autoimmune Pulmonary Alveolar Proteinosis (aPAP) is a rare lung disorder.
Pathogenesis involves GM-CSF neutralizing autoantibodies (GMAbs), leading to surfactant accumulation and immune deficiency.
Current therapy, Whole Lung Lavage (WLL), is invasive.

Purpose of the Study:

To evaluate the efficacy and safety of inhaled recombinant GM-CSF (rGM-CSF) for aPAP treatment.
To explore rGM-CSF as a pathogenesis-driven therapy.
To assess rGM-CSF's potential as an alternative or adjunct to WLL.

Main Methods:

Phase II and III clinical studies involving adult aPAP patients.
Daily administration of inhaled molgramostim (a type of rGM-CSF).
Comparison of outcomes against placebo, including pulmonary gas transfer and health status.

Main Results:

Inhaled molgramostim significantly improved pulmonary gas transfer and functional health status compared to placebo.
Adverse event rates were similar between the rGM-CSF and placebo groups.
rGM-CSF demonstrated a favorable safety profile with no dose-limiting toxicity in all studies.

Conclusions:

Inhaled rGM-CSF is a promising, safe, and effective treatment for aPAP.
rGM-CSF offers a less invasive, self-administered therapeutic option for patients.
WLL may be reserved as a rescue therapy for severe cases.